Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season

References

• Pharmacovigilance risk assessment committee (PRAC) EMA. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU; 2014 [accessed 2014 Apr 10]. https://www.ema.europa.eu/en/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu-scientific-guideline.
   Google Scholar
• Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, Gasparini R, Durando P, Icardi G. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2015;11(1):91–8. doi:10.4161/hv.34360.
   PubMed Web of Science ®Google Scholar
• Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Eurosurveillance. 2017;22(18). doi:10.2807/1560-7917.ES.2017.22.18.30527.
   Web of Science ®Google Scholar
• Chabanon AL, Wague S, Moureau A, Nissila M, Serradell L. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season. BMC Public Health. 2021;21(1):358. doi:10.1186/s12889-021-10378-8.
   PubMed Web of Science ®Google Scholar
• Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294–298.
   PubMedGoogle Scholar
• Gandhi-Banga S, Chabanon AL, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccin Immunother. 2019;15(9):2154–2158. doi:10.1080/21645515.2019.1581538.
   PubMed Web of Science ®Google Scholar
• Gandhi-Banga S, Wague S, Shrestha A, Syrkina O, Talanova O, Nissilä M, Stuff K, Monfredo C. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22. Influenza Other Respir Viruses. 2023;17(1):e13071. doi:10.1111/irv.13071.
   PubMed Web of Science ®Google Scholar
• Dos Santos G, Eckermann T, Martínez-Gómez X, Parra J, Nwoji U, Salamanca de la Cueva I. Enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring. Influenza Other Respir Viruses. 2023;17(3):e13098. doi:10.1111/irv.13098.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Seasonal influenza 2021–2022. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2022.
   Google Scholar
• European Centre for Disease Prevention and Control. Seasonal influenza 2022–2023. In: ECDC. Annual epidemiological report for 2023. Stockholm: ECDC; 2023.
   Google Scholar
• German Standing Committee on Vaccinations. Vaccination recommendations by STIKO. https://www.rki.de/EN/Content/infections/Vaccination/recommandations/recommendations_node.html.
   Google Scholar
• Sanofi Pasteur. Efluelda summary of product characteristics; 2023. http://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2131-015-001_23082023123426.pdf.
   Google Scholar
• Sanofi Pasteur. Vaxigrip tetra summary of product characteristics; 2022. https://www.medicines.org.uk/emc/product/666/smpc#gref.
   Google Scholar
• Finish Institute for Health and Welfare. Influenza vaccine. https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/influenza-vaccine.
   Google Scholar
• Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine Vaxigrip Tetra: preliminary results in children ≥6 months and older adults. Vaccines. 2018;6(1):14. doi:10.3390/vaccines6010014.
   Web of Science ®Google Scholar
• Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 y or older: a randomized phase III trial. Hum Vaccin Immunother. 2021;17(12):5475–5486. doi:10.1080/21645515.2021.1983387.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module V - Risk management systems (Rev 2); 2017 [accessed 2023 Dec 20]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf.
   Google Scholar
• Chabanon AL, Bricout H, Ballandras C, Souverain A, Caroe TD, Butler KM. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 mug) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Hum Vaccin Immunother. 2018;14(2):378–385. doi:10.1080/21645515.2017.1405882.
   PubMed Web of Science ®Google Scholar
• Bardenheier BH, Duderstadt SK, Engler RJ, McNeil MM. Adverse events following pandemic influenza a (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009–2010 season in the active component U.S. military and civilians aged 17–44y reported to the vaccine adverse event reporting system. Vaccine. 2016;34(37):4406–4414. doi:10.1016/j.vaccine.2016.07.019.
   PubMed Web of Science ®Google Scholar
• Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep. 2010;34:259–276.
   PubMedGoogle Scholar
• Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114–2120. doi:10.1016/j.vaccine.2009.01.125.
   PubMed Web of Science ®Google Scholar
• OFCOM. A review of Ofcom’s research on digital exclusion among adults in the UK; 2022 [accessed 2023 July 18]. https://www.ofcom.org.uk/__data/assets/pdf_file/0022/234364/digital-exclusion-review-2022.pdf.
   Google Scholar
• Syrkina O, Inamdar A, Wague S, Monfredo C, Nissilä M, Chabanon A-L, Serradell L. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21. BMC Public Health. in press. doi:10.1186/s12889-021-10378-8.
   Web of Science ®Google Scholar
• Serradell L, Wagué S, Moureau A, Nissilä M, Chabanon AL. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season. Hum Vaccin Immunother. 2021;17(4):1205–1210. doi:10.1080/21645515.2020.1804247.
   PubMed Web of Science ®Google Scholar